Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Cancer: early-phase trial registry
146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #12 of 28,707 conditions by registered trial count.
430 US clinical trials · 146 currently recruiting · #12 of 28,707 conditions by registered trial count
Lung Cancer: 430 US clinical trials tracked, 146 recruiting.
Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.
Enrollment posture brief
Registry condition lung-cancer
OPEN 146 | RECR 34% | LATE 23 | EARLY 181 | RANK #12 | SPON 36
Volume-matched condition peers
Nearest open-share peer: Solid Tumors (34% recruiting · 127 trials)
Lung Cancer lists 146 open slots (34% of 430 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Cancer is recruiting below its size-band peers.
146 of 430 indexed trials (34%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lung Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.
-
Typical Lung Cancer enrolment sits around 89 participants.
Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.
-
Lung Cancer research is mostly interventional.
321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
430 total, page 2 of 9
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
Georgetown University
NCT04675476
Adaptation and Pilot Testing of a Lung Cancer Screening Decision Aid for Patients From a Safety-Net Healthcare System
M.D. Anderson Cancer Center
NCT07382557
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Taiho Oncology
NCT07128199
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
NCT04916990
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners
M.D. Anderson Cancer Center
NCT02596490
Precision Lung Cancer Survivorship Care Intervention
Jerod L Stapleton, PhD
NCT05857995
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
Abramson Cancer Center at Penn Medicine
NCT05968898
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
NCT05800587
Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening
Washington University School of Medicine
NCT06898333
Study of Novel Treatment Combinations in Patients With Lung Cancer
Gilead Sciences
NCT05633667
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
Massachusetts General Hospital
NCT06427954
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
Vanderbilt-Ingram Cancer Center
NCT06105801
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
University of Colorado, Denver
NCT03881098
Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment
Laurie McLouth
NCT06047301
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Canadian Cancer Trials Group
NCT04093167
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT06577987
Confocal Laser Endomicroscopy VERification
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
NCT06079970
Metabolic Biomarkers in Thoracic Cancers
University of Texas Southwestern Medical Center
NCT02095808
Image Guided VATS vs. VATS Resection
Brigham and Women's Hospital
NCT03623958
Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center
M.D. Anderson Cancer Center
NCT06420206
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Stanford University
NCT00568490
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
The Cooper Health System
NCT05203328
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics
NCT06810544
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics
NCT06922591
Healthy Homes Study
Dartmouth-Hitchcock Medical Center
NCT05833334
Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling
Penn State University
NCT05599321
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Brigham and Women's Hospital
NCT06252129
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
NCT05358548
Increasing Equity in Lung Cancer Screening
Indiana University
NCT06360822
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo
NCT06644768
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics
NCT04678648
A Study of Mental Health Care in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT06037954
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Tango Therapeutics
NCT05887492
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
Northwestern University
NCT05671887
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Bo Lu
NCT06410300
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
COPD Care Pathway Among Patients With Cancer
Wake Forest University Health Sciences
NCT05984680
Exercise as Maintenance Therapy in Advanced Lung Cancer
Indiana University
NCT06513663
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
The Cooper Health System
NCT06688422
Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer
University of Rochester
NCT03706027
Community Support Program for Lung Cancer Screening Volume II
Abramson Cancer Center at Penn Medicine
NCT06628167
The Florida ASCENT Study
University of Florida
NCT07042243
Leveraging the Emergency Department (LEAD) Study
Hackensack Meridian Health
NCT06605534
4D-MRI for Precision Medicine
University of Virginia
NCT04657042
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Massachusetts General Hospital
NCT03535545
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 96 |
| Phase 3 | 22 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Cancer page
430 registered trials, 146 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 146 Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Cancer condition card totals 430 registered trials; most-linked intervention paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.